Dr. Reddy's Laboratories Limited

rs,

he Governments in our key global markets; Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry; Increasing competition in and the conditions of our cus

11%

sales growth with steady profitability FINANCIAL HIGHLIGHTS BUSINESS UPDATES  Revenue growth ~ 11%  EBITDA Margin ~ 26.7%  Annualised RoCE at ~ 22%  Net Cash surplus at ₹ 2,922 Cr  Collabo

26.7%

y profitability FINANCIAL HIGHLIGHTS BUSINESS UPDATES  Revenue growth ~ 11%  EBITDA Margin ~ 26.7%  Annualised RoCE at ~ 22%  Net Cash surplus at ₹ 2,922 Cr  Collaborated with Alvotech for co

22%

LIGHTS BUSINESS UPDATES  Revenue growth ~ 11%  EBITDA Margin ~ 26.7%  Annualised RoCE at ~ 22%  Net Cash surplus at ₹ 2,922 Cr  Collaborated with Alvotech for co- development, manufacture &

₹ 2,922

Revenue growth ~ 11%  EBITDA Margin ~ 26.7%  Annualised RoCE at ~ 22%  Net Cash surplus at ₹ 2,922 Cr  Collaborated with Alvotech for co- development, manufacture & commercialization of pembrolizu

₹ 8,545

te rating of ‘A’ while maintaining leadership in Water & Supplier Engagement Q1FY26 Performance ₹ 8,545 Cr Revenues 11%YoY 0% QoQ ₹ 2,278 Cr | 26.7% EBITDA | EBITDA % 5%YoY 8% QoQ ₹ 1,905 Cr | 22%

0%

ining leadership in Water & Supplier Engagement Q1FY26 Performance ₹ 8,545 Cr Revenues 11%YoY 0% QoQ ₹ 2,278 Cr | 26.7% EBITDA | EBITDA % 5%YoY 8% QoQ ₹ 1,905 Cr | 22% PBT | PBT % 1%YoY 5% Q

₹ 2,278

adership in Water & Supplier Engagement Q1FY26 Performance ₹ 8,545 Cr Revenues 11%YoY 0% QoQ ₹ 2,278 Cr | 26.7% EBITDA | EBITDA % 5%YoY 8% QoQ ₹ 1,905 Cr | 22% PBT | PBT % 1%YoY 5% QoQ ₹ 1,418 Cr

5%

nt Q1FY26 Performance ₹ 8,545 Cr Revenues 11%YoY 0% QoQ ₹ 2,278 Cr | 26.7% EBITDA | EBITDA % 5%YoY 8% QoQ ₹ 1,905 Cr | 22% PBT | PBT % 1%YoY 5% QoQ ₹ 1,418 Cr | 17% *PAT | PAT % 2%YoY 11%

8%

Y26 Performance ₹ 8,545 Cr Revenues 11%YoY 0% QoQ ₹ 2,278 Cr | 26.7% EBITDA | EBITDA % 5%YoY 8% QoQ ₹ 1,905 Cr | 22% PBT | PBT % 1%YoY 5% QoQ ₹ 1,418 Cr | 17% *PAT | PAT % 2%YoY 11% QoQ ^

₹ 1,905

ormance ₹ 8,545 Cr Revenues 11%YoY 0% QoQ ₹ 2,278 Cr | 26.7% EBITDA | EBITDA % 5%YoY 8% QoQ ₹ 1,905 Cr | 22% PBT | PBT % 1%YoY 5% QoQ ₹ 1,418 Cr | 17% *PAT | PAT % 2%YoY 11% QoQ ^After adjustin

1%

11%YoY 0% QoQ ₹ 2,278 Cr | 26.7% EBITDA | EBITDA % 5%YoY 8% QoQ ₹ 1,905 Cr | 22% PBT | PBT % 1%YoY 5% QoQ ₹ 1,418 Cr | 17% *PAT | PAT % 2%YoY 11% QoQ ^After adjusting for minority interest

Growth in Constant currency

1

Growth in Constant currency

+17% YoY Volume growth and favourable forex ₹ 195 Cr CISR RoW 36% 2%YoY 20% QoQ  QoQ decline due to lower volumes ₹ 501 Cr RoW 13%YoY 0% QoQ   YoY: Volume gains, new launches, moderated by price erosion QoQ: Increased volumes offset by price erosion NEW LAUNCHES 26 Q1 Across markets 8 | July 23, 2025 | Q1FY26 Results Update | As per consolidated financial statements under IFRS 8 Revenue gains from NRT portfolio and product launches REVENUE SPLIT Acquired NRT Business 52% France, Italy, Others 9% UK 14% Germany 25% ₹ 669 Cr Acquired NRT Business 12% QoQ ₹ 316 Cr Germany 13%YoY 11% QoQ ₹ 173 Cr UK 10%YoY 20% QoQ ₹ 116 Cr France, Italy, Others 30%YoY 9% QoQ NEW LAUNCHES 13 Q1 Excluding NRT Europe Q1FY26 Performance 15% Revenues ₹ 1,274* Cr 142%YoY 0% QoQ GROWTH DRIVERS  NRT business  New product launches, partially moderated by price erosion *Includes revenues from acquired NRT business. 9 | July 23, 2025 | Q1FY26 Results Update | As per consolidated financial statements under IFRS 9